AdvaMed® Q1 2026: Driving Momentum in a Shifting Policy Landscape
The first quarter of 2026 highlighted how quickly policy and regulatory developments are shaping the future of medtech innovation and patient access. As new priorities emerged across Washington and global markets, the need for clear, consistent advocacy remained critical.
AdvaMed® ensured the industry’s voice was represented at key decision points—bringing forward data, real-world evidence, and frontline perspectives to inform policy discussions. Across regulatory, reimbursement, and innovation priorities, the focus remained on advancing patient access and supporting a stable environment for continued growth
From shaping emerging policy frameworks to reinforcing the value of medical technology, Q1 set the tone for the year ahead. See how advocacy and strategic action are driving impact for members and the entire medtech ecosystem.